强大的中和SARS-CoV-2变体由RBD纳米粒子和预注射稳定尖端免疫原体
Marcos C Miranda1,2, Elizabeth Kepl1,2, Mary Jane Navarro1
1Department of Biochemistry, University of Washington, Seattle, WA, USA.
NPJ vaccines
|October 8, 2024
概括
两组分蛋白质纳米粒子 (RBD-NP) 疫苗平台显示了针对SARS-CoV-2变种的广泛保护的潜力. 这种平台可以快速适应和稳定,用于变种特定的疫苗开发,从而引起强大的中和抗体反应.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 蛋白质纳米粒子技术的技术
- 冠状病毒 冠状病毒
背景情况:
- 一种具有SARS-CoV-2尖端蛋白质受体结合域 (RBDs) 的两组分蛋白质纳米粒子疫苗 (RBD-NP) 已经证明有效.
- 这种平台在辅助时,在临床试验中引起了强烈的免疫反应,并且作为SKYCovioneTM获得许可.
研究的目的:
- 描述来自SARS-CoV-2变种突变的RBD-NP免疫原体的生物物理性质,稳定性,抗原性和免疫性 (B.1.351,P.1,Omicron BA.5,XBB.1.5).
- 评估该平台的适应性和稳定性,以开发不同的疫苗,并将其与其他免疫原型进行比较.
主要方法:
- 包含变异突变的RBD-NP免疫原体的表征 (β, γ, E484K,奥米克朗BA.5,XBB.1.5).
- 变种RBD-NP与Wu-1 RBD-NP和可溶性预注液稳定 (HexaPro) 尖端剪裁器的比较.
- 通过引入突变评估物理稳定性,评估免疫性和中和抗体对各种SARS-CoV-2变异的反应.
主要成果:
- 基于变异的免疫原体的特性发生了显著的变化,影响了发育活力.
- 稳定RBD-NP中的突变增强了物理稳定性,而不会影响免疫性.
- RBD-NP 免疫原和 HexaPro trimers 诱导了与不同 SARS-CoV-2 变体相比较的中和抗体水平.
结论:
- 该RBD-NP平台可以快速设计和稳定,以引起针对SARS-CoV-2变种的中和抗体.
- 这表明了两组RBD-NP在开发广泛保护的冠状病毒疫苗方面的潜力.
相关概念视频
01:29Coronavirus
Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...